CoChat

Prospective clinical trial of hepatitis B vaccination in adults with and without type-2 diabetes mellitus

Open access
Van Der Meeren, Olivier, Peterson, James T., Dionne, Marc, Beasley, Richard, Ebeling, Peter R., Ferguson, Murdo, Nissen, Michael D., Rheault, Paul, Simpson, Richard W., De Ridder, Marc, Crasta, Priya D., Miller, Jacqueline M., Trofa, Andrew F. · 2016 · Human Vaccines & Immunotherapeutics

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Abstract

Objective: Patients with diabetes mellitus are at increased risk for hepatitis B virus (HBV) infection and its complications. HBV vaccination is recommended for adults with diabetes in the United States and other countries. However, few studies have assessed safety and immunogenicity of hepatitis B vaccine in such patients. We assessed the safety and immunogenicity of recombinant hepatitis B vaccine in subjects with and without diabetes mellitus. METHODS: Prospective, multi-country controlled study in 21 centers ( www.clinicaltrials.gov NCT01627340). Four hundred and sixteen participants with Type-2 diabetes and 258 controls matched for age and body mass index (BMI) (2:1 ratio) received 3-doses of HBV vaccine (Engerix-B™, GSK Vaccines, Belgium) according to a 0, 1, 6 months schedule. Antibodies were measured against HBV surface antigen and expressed as seroprotection rates (anti-HBs ≥10mIU/mL) and geometric mean concentration (GMC). RESULTS: , respectively. Seroprotection rates (GMCs) one month post-dose-3 were 75.4% (147.6 mIU/mL) and 82.0% (384.2 mIU/mL) in patients with diabetes and controls, respectively. Age-stratified seroprotection rates for patients with diabetes were 88.5% (20-39 years), 81.2% (40-49 years), 83.2% (50-59 years), and 58.2% (≥60 years). The overall safety profile of hepatitis B vaccine was similar between groups. CONCLUSIONS: Hepatitis B vaccine is immunogenic in patients with diabetes and has a similar safety profile to vaccination in healthy controls. Because increasing age was generally associated with a reduction in seroprotection rates, hepatitis B vaccine should be administered as soon as possible after the diagnosis of diabetes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/21645515.2016.1164362

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 29 references

Research works printed but not linked: 3

  1. Farkas K, Jermendy G Transmission of hepatitis B infection during home blood glucose monitoring. Diabet Med 1997; 14(3): 263; http://dx.doi.org/ 10.1002/(SICI)1096-9136(199703)14:3%3c263::AID-DIA342%3e3.0.CO;2-R 9088777 · doi:10.1002/(sici)1096-9136(199703)14:3<263::aid-dia342>3.0.co;2-r
  2. 10.1002/(sici)1096-9136(199703)14:3%3c263::aid-dia342%3e3.0.co;2-r · doi:10.1002/(sici)1096-9136(199703)14:3<263::aid-dia342>3.0.co;2-r
  3. Public Health Agency of Canada Canadian Immunization Guide. Part 4 Active Vaccines. Hepatitis B Vaccine [article online]. Ottowa: 2015, Public Health Agency of Canada. Available from: http://www.phac-aspc.gc.ca/publicat/cig-gci/p04-hepb-eng.php [Accessed 20 2 2015].

Cited by

See all 34

Metadata

Authors
Van Der Meeren, O., Peterson, J. T., Dionne, M., Beasley, R., Ebeling, P. R., Ferguson, M., Nissen, M. D., Rheault, P., Simpson, R. W., De Ridder, M., Crasta, P. D., Miller, J. M., & Trofa, A. F.
Affiliations
  • Centre hospitalier universitaire de Québec (CA)
  • Medical Research Institute of New Zealand (NZ)
  • Monash University (AU)
  • The University of Queensland (AU)
  • Eastern Health (AU)
  • GlaxoSmithKline (India) (IN)
  • GlaxoSmithKline (United States) (US)
Venue
Human Vaccines & Immunotherapeutics
Published
2016-04-28
Volume
12
Issue
8
Pages
2197-2203
ISSN
  • 2164-5515 (ISSN-L)
  • 2164-554X
OpenAlex
W2345116174
Cited by
34
References
29
Citations by year
2026: 2 · 2025: 2 · 2024: 5 · 2023: 2 · 2022: 5 · 2021: 5 · 2020: 7 · 2019: 3 · 2018: 1 · 2017: 2
FWCI
1.88
Type
journal article
Language
en
Open access
Locations
  • Human Vaccines & Immunotherapeutics (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • Monash University Research Portal (Monash University) (publishedVersion, other-oa)
  • PubMed (publishedVersion)
  • Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion, other-oa)
  • Minerva Access (University of Melbourne) (submittedVersion, cc-by-nc)
Funders
GlaxoSmithKline
Topics
  • Health Sciences › Medicine › Epidemiology › Hepatitis B Virus Studies
  • Health Sciences › Medicine › Emergency Medicine › Intramuscular injections and effects
  • Health Sciences › Medicine › Hepatology › Hepatitis C virus research
Keywords
hepatitis B vaccination, type 2 diabetes, recombinant hepatitis B vaccine, Engerix-B, vaccine immunogenicity, vaccine safety, seroprotection rate, anti-HBs antibodies
MeSH terms
Adult, Aged, Aged, 80 and over, Diabetes Mellitus, Type 2, Female, Hepatitis B Antibodies, Hepatitis B Surface Antigens, Humans, Male, Middle Aged, Prospective Studies, Vaccines, Synthetic, Hepatitis B Vaccines, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Prospective clinical trial of hepatitis B vaccination in adults with and without type-2 diabetes mellitus. https://app.cochat.ai/papers/10.1080/21645515.2016.1164362
The paper
Van Der Meeren, O., Peterson, J. T., Dionne, M., Beasley, R., Ebeling, P. R., Ferguson, M., Nissen, M. D., Rheault, P., Simpson, R. W., De Ridder, M., Crasta, P. D., Miller, J. M., & Trofa, A. F. (2016). Prospective clinical trial of hepatitis B vaccination in adults with and without type-2 diabetes mellitus. Human Vaccines & Immunotherapeutics. https://doi.org/10.1080/21645515.2016.1164362

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.